NTLA INTELLIA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, INTELLIA THERAPEUTICS INC reported revenue of $7.66M (down 46.2% from a year earlier), net income of −$107M and diluted EPS of −$0.80; over the last four quarters revenue was $59.5M and net income −$400M; for the fiscal year ended December 2025 revenue was $67.7M, up 16.9% on the year before.

NTLA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $67.7M, gross profit n/a, operating income −$441M, net income −$413M (margin -609.9%), EPS −$3.81
• Fiscal year ended Dec 2024: revenue $57.9M, gross profit n/a, operating income −$534M, net income −$519M (margin -896.8%), EPS −$5.25
• Fiscal year ended Dec 2023: revenue $36.3M, gross profit n/a, operating income −$515M, net income −$481M (margin -1326.5%), EPS −$5.42
• Fiscal year ended Dec 2022: revenue $52.1M, gross profit n/a, operating income −$458M, net income −$474M (margin -909.8%), EPS −$6.16
• Fiscal year ended Dec 2021: revenue $33.1M, gross profit n/a, operating income −$268M, net income −$268M (margin -810.5%), EPS −$3.78

NTLA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $7.66M (down 46.2% year over year), net income −$107M, EPS −$0.80
• Quarter ended Mar 31, 2026: revenue $15.0M (down 9.5% year over year), net income −$96.2M, EPS −$0.81
• Quarter ended Dec 31, 2025 (from the annual report): revenue $23.0M (up 78.8% year over year), net income −$95.8M, EPS −$0.81
• Quarter ended Sep 30, 2025: revenue $13.8M (up 51.3% year over year), net income −$101M, EPS −$0.92
• Quarter ended Jun 30, 2025: revenue $14.2M (up 104.8% year over year), net income −$101M, EPS −$0.98
• Quarter ended Mar 31, 2025: revenue $16.6M (down 42.5% year over year), net income −$114M, EPS −$1.10
• Quarter ended Dec 31, 2024 (from the annual report): revenue $12.9M (up 771.6% year over year), net income −$129M, EPS −$1.27
• Quarter ended Sep 30, 2024: revenue $9.11M (down 24.0% year over year), net income −$136M, EPS −$1.34
• Quarter ended Jun 30, 2024: revenue $6.96M (down 48.8% year over year), net income −$147M, EPS −$1.52
• Quarter ended Mar 31, 2024: revenue $28.9M (up 129.5% year over year), net income −$107M, EPS −$1.12
• Quarter ended Dec 31, 2023 (from the annual report): revenue −$1.92M (down 114.1% year over year), net income −$132M, EPS −$1.47
• Quarter ended Sep 30, 2023: revenue $12.0M (down 9.6% year over year), net income −$122M, EPS −$1.38
• Quarter ended Jun 30, 2023: revenue $13.6M (down 3.1% year over year), net income −$124M, EPS −$1.40
• Quarter ended Mar 31, 2023: revenue $12.6M (up 12.0% year over year), net income −$103M, EPS −$1.17
• Quarter ended Dec 31, 2022 (from the annual report): revenue $13.6M (up 5.6% year over year), net income −$113M, EPS −$1.38
• Quarter ended Sep 30, 2022: revenue $13.3M (up 84.1% year over year), net income −$113M, EPS −$1.49
• Quarter ended Jun 30, 2022: revenue $14.0M (up 114.2% year over year), net income −$101M, EPS −$1.33
• Quarter ended Mar 31, 2022: revenue $11.3M (up 74.6% year over year), net income −$147M, EPS −$1.96
• Quarter ended Dec 31, 2021 (from the annual report): revenue $12.9M, net income −$81.2M, EPS −$1.11
• Quarter ended Sep 30, 2021: revenue $7.20M, net income −$71.6M, EPS −$0.97

NTLA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$395M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$349M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$394M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$333M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$225M, share buybacks n/a

NTLA balance sheet

• Jun 30, 2026: cash $106M, total assets $857M, total liabilities $129M, shareholders' equity $728M
• Mar 31, 2026: cash $135M, total assets $759M, total liabilities $138M, shareholders' equity $621M
• Dec 31, 2025: cash $155M, total assets $842M, total liabilities $171M, shareholders' equity $671M
• Sep 30, 2025: cash $193M, total assets $925M, total liabilities $177M, shareholders' equity $748M
• Jun 30, 2025: cash $156M, total assets $899M, total liabilities $184M, shareholders' equity −$715M
• Mar 31, 2025: cash $127M, total assets $986M, total liabilities $206M, shareholders' equity $780M
• Dec 31, 2024: cash $189M, total assets $1.19B, total liabilities $319M, shareholders' equity $872M
• Sep 30, 2024: cash $120M, total assets $1.17B, total liabilities $211M, shareholders' equity $963M

What is NTLA's revenue?

INTELLIA THERAPEUTICS INC reported $59.5M of revenue over its last four quarters, through June 30, 2026.

Is NTLA profitable?

No. INTELLIA THERAPEUTICS INC lost $400M over the last four quarters.

What is NTLA's EPS?

Diluted earnings per share over the last four quarters were −$3.34; −$0.80 in the latest quarter.

NTLA ownership and insider trades · All stocks